Free tool
FAERS Monitor: Daunorubicin Hydrochloride
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050731 or its brand name (Daunorubicin Hydrochloride, Daunorubicin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,648
Serious
1,634
99% of reports
Hospitalization
767
Death reported
398
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- febrile neutropenia205
- myelosuppression187
- bacterial infection158
- secondary immunodeficiency130
- pyrexia127
- clostridium difficile colitis115
- off label use109
- pancytopenia95
- fungal infection91
- viral infection86
- pneumonia80
- product use in unapproved indication80
- neutropenia73
- cytomegalovirus viraemia70
- bronchopulmonary aspergillosis69
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 11 |
| 2006 | 6 |
| 2007 | 10 |
| 2008 | 8 |
| 2009 | 8 |
| 2010 | 7 |
| 2011 | 23 |
| 2012 | 92 |
| 2013 | 32 |
| 2014 | 17 |
| 2015 | 26 |
| 2016 | 21 |
| 2017 | 36 |
| 2018 | 98 |
| 2019 | 108 |
| 2020 | 111 |
| 2021 | 127 |
| 2022 | 203 |
| 2023 | 212 |
| 2024 | 204 |
| 2025 | 123 |
| 2026 | 159 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,511 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| secondary immunodeficiencySignal | 130 | 1530.6 | 1284.4 | 176,102 |
| cytomegalovirus viraemiaSignal | 70 | 204.0 | 161.9 | 13,723 |
| clostridium difficile colitisSignal | 115 | 140.0 | 117.2 | 15,564 |
| bronchopulmonary aspergillosisSignal | 69 | 114.6 | 90.9 | 7,590 |
| bacterial infectionSignal | 158 | 109.0 | 93.9 | 16,674 |
| myelosuppressionSignal | 187 | 66.6 | 58.2 | 11,976 |
| febrile neutropeniaSignal | 205 | 39.6 | 34.8 | 7,667 |
| fungal infectionSignal | 91 | 34.9 | 28.6 | 2,963 |
| viral infectionSignal | 86 | 33.1 | 26.9 | 2,640 |
| pancytopeniaSignal | 95 | 21.7 | 17.9 | 1,860 |
| neutropeniaSignal | 73 | 6.9 | 5.5 | 361 |
| pyrexiaSignal | 127 | 4.7 | 4.0 | 370 |
| product use in unapproved indicationSignal | 80 | 4.1 | 3.3 | 188 |
| pneumoniaSignal | 80 | 3.2 | 2.5 | 117 |
| off label use | 109 | 1.6 | 1.3 | 24 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.